Research Analysts Set Expectations for NovoCure Q2 Earnings

NovoCure Limited (NASDAQ:NVCR) – Investment analysts at HC Wainwright upped their Q2 2026 EPS estimates for NovoCure in a research note issued on Thursday, July 23rd. HC Wainwright analyst E. Bodnar now forecasts that the medical equipment provider will post earnings per share of ($0.13) for the quarter, up from their prior forecast of ($0.23). The consensus estimate for NovoCure’s current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for NovoCure’s Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($1.05) EPS, FY2027 earnings at ($1.06) EPS, FY2028 earnings at ($0.37) EPS and FY2030 earnings at $4.53 EPS.

Several other research firms have also recently commented on NVCR. Evercore reaffirmed an “outperform” rating on shares of NovoCure in a research note on Friday, May 1st. Weiss Ratings raised NovoCure from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 1st. Zacks Research cut NovoCure from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Wells Fargo & Company raised their price objective on shares of NovoCure from $13.50 to $17.00 and gave the stock an “equal weight” rating in a research report on Monday, May 4th. Finally, JPMorgan Chase & Co. began coverage on shares of NovoCure in a research note on Monday, July 13th. They issued a “neutral” rating and a $17.00 price objective for the company. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $21.20.

NovoCure Stock Down 3.5%

Shares of NASDAQ:NVCR opened at $17.03 on Monday. The company has a market capitalization of $1.97 billion, a price-to-earnings ratio of -13.10 and a beta of 0.94. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.89 and a quick ratio of 2.70. The business’s 50-day moving average is $16.63 and its 200-day moving average is $14.16. NovoCure has a 1 year low of $9.82 and a 1 year high of $21.45.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings results on Thursday, July 23rd. The medical equipment provider reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.20. NovoCure had a negative return on equity of 44.00% and a negative net margin of 21.25%.The firm had revenue of $183.58 million during the quarter, compared to the consensus estimate of $172.44 million. During the same period last year, the business posted ($0.36) EPS. The business’s revenue was up 15.6% compared to the same quarter last year.

Institutional Trading of NovoCure

Hedge funds and other institutional investors have recently bought and sold shares of the company. Empowered Funds LLC purchased a new position in shares of NovoCure during the fourth quarter worth approximately $33,000. Kestra Advisory Services LLC purchased a new stake in shares of NovoCure in the 4th quarter valued at $49,000. Larson Financial Group LLC grew its holdings in shares of NovoCure by 662.1% during the 3rd quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock valued at $53,000 after purchasing an additional 3,562 shares during the last quarter. Headlands Technologies LLC bought a new position in shares of NovoCure during the 2nd quarter valued at $88,000. Finally, Acadian Asset Management LLC purchased a new position in NovoCure in the 1st quarter worth $87,000. Hedge funds and other institutional investors own 84.61% of the company’s stock.

Insider Activity

In other NovoCure news, CEO Frank X. Leonard sold 34,273 shares of NovoCure stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $17.93, for a total transaction of $614,514.89. Following the completion of the sale, the chief executive officer owned 459,520 shares of the company’s stock, valued at $8,239,193.60. The trade was a 6.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeryl L. Hilleman sold 2,945 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $15.77, for a total value of $46,442.65. Following the completion of the transaction, the director owned 13,861 shares of the company’s stock, valued at $218,587.97. The trade was a 17.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 51,943 shares of company stock valued at $893,171. 5.52% of the stock is currently owned by corporate insiders.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.